BR0015698A - Composições e métodos para tratamento de doenças alérgicas - Google Patents

Composições e métodos para tratamento de doenças alérgicas

Info

Publication number
BR0015698A
BR0015698A BR0015698-1A BR0015698A BR0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A
Authority
BR
Brazil
Prior art keywords
methods
compositions
allergic diseases
treating allergic
relates
Prior art date
Application number
BR0015698-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Llewellyn Clancy
Gerald Pang
Original Assignee
Probiall Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiall Pty Ltd filed Critical Probiall Pty Ltd
Publication of BR0015698A publication Critical patent/BR0015698A/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/07Bacillus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866Interferon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/113Acidophilus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/125Casei
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR0015698-1A 1999-11-19 2000-11-20 Composições e métodos para tratamento de doenças alérgicas BR0015698A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases
PCT/AU2000/001414 WO2001037865A1 (fr) 1999-11-19 2000-11-20 Compositions et methodes pour le traitement des troubles allergiques

Publications (1)

Publication Number Publication Date
BR0015698A true BR0015698A (pt) 2002-07-23

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015698-1A BR0015698A (pt) 1999-11-19 2000-11-20 Composições e métodos para tratamento de doenças alérgicas

Country Status (9)

Country Link
EP (1) EP1229930A4 (fr)
JP (1) JP2003514869A (fr)
KR (1) KR20020084066A (fr)
CN (1) CN1391480A (fr)
AU (1) AUPQ415899A0 (fr)
BR (1) BR0015698A (fr)
CA (1) CA2391499A1 (fr)
HK (1) HK1049115A1 (fr)
WO (1) WO2001037865A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
CA2518947A1 (fr) * 2003-03-13 2004-11-11 Kirin Beer Kabushiki Kaisha Composition antiallergique
JP4712289B2 (ja) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ 免疫促進用組成物
JP4591810B2 (ja) * 2003-09-19 2010-12-01 日之出産業株式会社 花粉症アレルギー性鼻炎抑制用点鼻組成物
CN100421676C (zh) * 2003-12-17 2008-10-01 纽迪西亚公司 乳酸产生细菌和肺功能
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
TWI356680B (en) * 2007-01-05 2012-01-21 Promd Biotech Co Ltd Anti-allergy lactic acid bacteria
CN101328468B (zh) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 抗过敏的乳酸菌
CN102657260B (zh) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 抗过敏的乳酸菌
EP2065048A1 (fr) * 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
PL2244734T3 (pl) 2008-02-01 2017-01-31 Murdoch Childrens Research Institute Sposób indukcji tolerancji na alergen
EP2603208B1 (fr) 2010-08-10 2014-06-04 R.P. Scherer Technologies, LLC Procédé de fabrication d'une capsule molle stable contenant des bactéries probiotiques micro-encapsulées
KR101311989B1 (ko) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품
PE20210108A1 (es) * 2018-01-12 2021-01-19 Gi Innovation Inc Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma
CN111296842B (zh) * 2020-02-14 2021-01-05 赵一鸣 一种具有抗敏作用的益生菌组合物
CN112375722B (zh) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 一种改善过敏的干酪乳杆菌lc-12及其产品、应用
WO2024081219A1 (fr) 2022-10-14 2024-04-18 Csp Technologies, Inc. Récipient et procédé de stockage et de stabilisation de produits sensibles à l'humidité
CN117085046A (zh) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 嗜酸乳杆菌ls001后生元及其应用
CN117887643B (zh) * 2024-03-14 2024-06-14 微康益生菌(苏州)股份有限公司 一种抗过敏的益生菌剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (ja) 1978-08-07 1984-11-13 極東脂肪酸株式会社 アレルギ−反応抑制剤
JPS5946491B2 (ja) 1979-03-14 1984-11-13 極東脂肪酸株式会社 喘息治療剤
JPH07265064A (ja) 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd IgE抗体産生抑制剤および抗アレルギー剤
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
JPH11199495A (ja) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk 腸溶性カプセルを用いた抗アレルギー剤
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
JP4074006B2 (ja) * 1998-06-24 2008-04-09 アサマ化成株式会社 IgE抗体産生抑制物質の製造方法並びにそれを用いた食品

Also Published As

Publication number Publication date
AUPQ415899A0 (en) 1999-12-16
EP1229930A4 (fr) 2004-09-22
JP2003514869A (ja) 2003-04-22
HK1049115A1 (zh) 2003-05-02
CA2391499A1 (fr) 2001-05-31
EP1229930A1 (fr) 2002-08-14
CN1391480A (zh) 2003-01-15
KR20020084066A (ko) 2002-11-04
WO2001037865A1 (fr) 2001-05-31

Similar Documents

Publication Publication Date Title
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
ATE290391T1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
GB0223040D0 (en) Therapeutic compounds
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DK1483366T3 (da) Antimikrobiel sammensætning
ZA943744B (en) Therapeutic substituted guanidines
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
DE602004013146D1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
DE69840027D1 (de) Synthetische peptidkonstrukte zur erkennung und behandlung von parodontose hervorgerufen durch porphyromonas gingivalis
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
ATE267816T1 (de) Tan-1057 derivate
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
AU4568400A (en) Sphingomyelinase inhibitor
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PROBIALL PTY LIMITED (AU)

Free format text: ANOTADAS AS ALTERACOES DE SEDE CONFORME A PETICAO NO 020060046936/RJ DE 04/04/2006.

B25A Requested transfer of rights approved

Owner name: ROBERT CLANCY (AU)

Free format text: TRANSFERIDO DE: PROBIALL PTY LIMITED

B25A Requested transfer of rights approved

Owner name: DSM IP ASSETS B.V. (NL)

Free format text: TRANSFERIDO DE: ROBERT CLANCY

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.